Lee W.-S.PO-REN HSUEHHsieh T.-C.Chen F.-L.Ou T.-Y.Jean S.-S.2020-12-182020-12-1820171684-1182https://scholars.lib.ntu.edu.tw/handle/123456789/528238[SDGs]SDG3caspofungin; cotrimoxazole; efavirenz; lamivudine plus zidovudine; methenamine; prednisolone; anti human immunodeficiency virus agent; antifungal agent; caspofungin; adult; case report; CD4 lymphocyte count; clinical article; computer assisted tomography; drug substitution; drug withdrawal; dyspnea; fever; fungal cell wall; human; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; image analysis; Letter; leukopenia; loading drug dose; lung infiltrate; lung lavage; maintenance therapy; male; middle aged; Pneumocystis jiroveci; Pneumocystis pneumonia; rash; salvage therapy; silver staining; thorax radiography; treatment outcome; treatment response; AIDS related complex; bronchoalveolar lavage fluid; drug effect; highly active antiretroviral therapy; isolation and purification; microbiology; pathology; Pneumocystis carinii; Pneumocystis pneumonia; Taiwan; x-ray computed tomography; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; Bronchoalveolar Lavage Fluid; Caspofungin; CD4 Lymphocyte Count; Humans; Male; Middle Aged; Pneumocystis carinii; Pneumonia, Pneumocystis; Salvage Therapy; Taiwan; Tomography, X-Ray Computed; Treatment Outcomeletter10.1016/j.jmii.2016.03.008270943852-s2.0-84963632203